UCH-L1/PGP9.5 Antibody [DyLight 405]

DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

UCH-L1 (ubiquitin carboxyl-terminal hydrolase isozyme L1) was the first discovered de-ubiquitinating enzyme which implicates in processing of ubiquitin precursors and also of ubiquitinated proteins. UCH-L1 is a thiol protease that recognizes and hydrolyzes a peptide bond at C-terminal glycine of ubiquitin. It also binds to free monoubiquitin and prevents its degradation in lysosomes. Localized in cytoplasm and ER membrane as lipid-anchor, UCH-L1 expression is restricted to brain, peripheral nerves, endocrine tissues and gonads of both sexes etc. UCH-L1 deletion in mice leads to fatal neurodegenerative disorder known as gracile axonal dystrophy and it is down-regulated in brains from Parkinson as well as Alzheimer disease patients. Expression outside of neuro-endocrine tissues is found in various cancers including B-cell lymphoma, multiple myeloma, and lung cancer. In transgenic mouse model, UCH-L1 has been demonstrated as an oncogene that causes malignancies by boosting AKT signalling. Furthermore, UCH-L1 has been shown to interfere with ubiquitination of RAPTOR which is catalyzed by DDB1-Cul4 E3 ligase complex, leading to loss of mTORC1 integrity accompanied by a concurrent increase in mTORC2, likely due to increased availability of free mTOR.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB300-676V

• UCH-L1/PGP9.5 Antibodies
• UCH-L1/PGP9.5 Lysate
• UCH-L1/PGP9.5 Proteins
• UCH-L1/PGP9.5 ELISA
• UCH-L1/PGP9.5 Proteins and Enzyme